Novartis AG [NYSE: NVS] closed the trading session at $83.01 on 07/13/22. The day’s price range saw the stock hit a low of $82.89, while the highest price level was $83.655. The company report on June 30, 2022 that New Phase III data show Novartis tislelizumab significantly extended median overall survival by more than 6 months in first-line advanced esophageal cancer in combination with chemotherapy.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
First-line tislelizumab plus chemotherapy showed median overall survival of 17.2 months versus 10.6 months for chemotherapy and reduced risk of death by 34% in patients with advanced esophageal squamous cell carcinoma1.
Statistically significant survival benefit with tislelizumab plus chemotherapy was observed regardless of PD-L1 status and consistent across all patient subgroups1.
The stocks have a year to date performance of -5.10 percent and weekly performance of -0.86 percent. The stock has been moved at -7.85 percent over the last six months. The stock has performed -2.41 percent around the most recent 30 days and changed -11.46 percent over the most recent 3-months.
If compared to the average trading volume of 2.30M shares, NVS reached to a volume of 3887457 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Novartis AG [NVS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NVS shares is $104.40 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NVS stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wolfe Research have made an estimate for Novartis AG shares, keeping their opinion on the stock as Peer Perform, with their previous recommendation back on May 09, 2022. While these analysts kept the previous recommendation, Citigroup raised their target price to Buy. The new note on the price target was released on January 10, 2022, representing the official price target for Novartis AG stock.
The Average True Range (ATR) for Novartis AG is set at 1.23, with the Price to Sales ratio for NVS stock in the period of the last 12 months amounting to 3.78. The Price to Book ratio for the last quarter was 3.00, with the Price to Cash per share for the same quarter was set at 7.80. Price to Free Cash Flow for NVS in the course of the last twelve months was 35.14 with Quick ratio for the last quarter at 1.00.
NVS stock trade performance evaluation
Novartis AG [NVS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.86. With this latest performance, NVS shares dropped by -2.41% in over the last four-week period, additionally sinking by -7.85% over the last 6 months – not to mention a drop of -10.42% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NVS stock in for the last two-week period is set at 40.58, with the RSI for the last a single of trading hit 38.07, and the three-weeks RSI is set at 41.98 for Novartis AG [NVS]. The present Moving Average for the last 50 days of trading for this stock 86.02, while it was recorded at 84.04 for the last single week of trading, and 85.62 for the last 200 days.
Novartis AG [NVS]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Novartis AG [NVS] shares currently have an operating margin of +23.11 and a Gross Margin at +69.27. Novartis AG’s Net Margin is presently recorded at +46.53.
Return on Total Capital for NVS is now 12.56, given the latest momentum, and Return on Invested Capital for the company is 27.67. Return on Equity for this stock inclined to 39.33, with Return on Assets sitting at 18.25. When it comes to the capital structure of this company, Novartis AG [NVS] has a Total Debt to Total Equity ratio set at 45.86. Additionally, NVS Total Debt to Total Capital is recorded at 31.44, with Total Debt to Total Assets ending up at 22.83. Long-Term Debt to Equity for the company is recorded at 36.25, with the Long-Term Debt to Total Capital now at 24.85.
Reflecting on the efficiency of the workforce at the company, Novartis AG [NVS] managed to generate an average of $210,515 per employee. Receivables Turnover for the company is 5.88 with a Total Asset Turnover recorded at a value of 0.39.Novartis AG’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.00 and a Current Ratio set at 1.20.
Earnings per share (EPS) analysis for Novartis AG [NVS] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NVS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Novartis AG go to 4.72%.
Novartis AG [NVS]: Insider Ownership positions
There are presently around $17,542 million, or 9.50% of NVS stock, in the hands of institutional investors. The top three institutional holders of NVS stocks are: DODGE & COX with ownership of 27,844,209, which is approximately -1.435% of the company’s market cap and around 9.30% of the total institutional ownership; PRIMECAP MANAGEMENT CO/CA/, holding 17,784,730 shares of the stock with an approximate value of $1.49 billion in NVS stocks shares; and LOOMIS SAYLES & CO L P, currently with $1.45 billion in NVS stock with ownership of nearly -3.277% of the company’s market capitalization.
Positions in Novartis AG stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 493 institutional holders increased their position in Novartis AG [NYSE:NVS] by around 11,406,457 shares. Additionally, 499 investors decreased positions by around 13,289,315 shares, while 226 investors held positions by with 184,282,090 shares. The mentioned changes placed institutional holdings at 208,977,862 shares, according to the latest SEC report filing. NVS stock had 82 new institutional investments in for a total of 2,998,338 shares, while 87 institutional investors sold positions of 3,270,371 shares during the same period.